A retrospective, descriptive analysis identifying non‑small cell lung cancer molecular markers.

molecular genetics non-small cell lung cancer

Journal

Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 13 11 2023
accepted: 27 03 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

Non-small-cell lung cancer (NSCLC) remains one of the leading causes of cancer mortality worldwide. The aim of the present study was to review the histologic patterns and molecular drivers of NSCLC in patients with lung cancer. The electronic health records (EHR) of all patients diagnosed with lung cancer between April 2015 and September 2022 were obtained from a tertiary care hospital and retrospectively analysed. A total of 224 patients were identified of which 192 (138 males and 54 females) were included in the final analysis. Adenocarcinoma was the most common type of lung cancer identified, and accounted for 134 patients (70%), followed by squamous cell carcinoma in 47 (24%) patients, while large cell lung cancer was noted in only 5 (3%) patients. The most common mutations were EGFR mutations and were detected in 29 (15%) patients, followed by PD-L1 expression which was present in 56 (24.7%) patients, KRAS in 16 (8.3%) patients, ALK1 in 8 (4.2%) patients and BRAF, ROS1 and MET were present in 3 (1.6%), 2 (1%) and 1 (0.5%), respectively. The findings from the present study offer important insights into the epidemiological, clinical and molecular characteristics of NSCLC. Further research is warranted to explore the clinical implications of these findings.

Identifiants

pubmed: 38756870
doi: 10.3892/mco.2024.2738
pii: MCO-20-6-02738
pmc: PMC11097133
doi:

Types de publication

Journal Article

Langues

eng

Pagination

41

Informations de copyright

Copyright: © 2024 Shafiq et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Auteurs

Irfan Shafiq (I)

Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates.

Said Isse (S)

Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates.

Naureen Khan (N)

Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates.

Mateen Uzebeck (M)

Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates.

Zaid Zoumot (Z)

Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates.

Safia Shabeer (S)

Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates.

Ali Wahla (A)

Respiratory Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi 112412, United Arab Emirates.

Classifications MeSH